The company was inspected last October and received a warning letter related to environmental monitoring activities in the processing facility that did not affect patient safety.
In the latest inspection, the FDA determined RTI has addressed the past problems and did not have new problems.
More Articles on Devices:
SI-BONE Reaches 25k Implantation Milestone for iFuse Device
Recently-Appointed InVivo Therapeutics Acting CFO Sean Moran Abruptly Resigns
Titan Spine Debuts Study Supporting its Device Surface Technology
